LILLY's PROZAC FOR OBSESSIVE-COMPULSIVE DISORDER
Executive Summary
LILLY's PROZAC FOR OBSESSIVE-COMPULSIVE DISORDER approved Feb. 28 with the conditions that Lilly conduct a relapse prevention trial and a pediatric OCD study and enhance certain sections of the adverse reaction section of labeling. The serotonin reuptake inhibitor fluoxetine has been approved since 1987 for the treatment of depression. The second indication is for the "treatment of obsessions and compulsions" in patients with OCD who have obsessions or compulsions that "cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning."